4RY.F AKESO INC. O.N.
- Market cap
- EUR 9.50B
- P/E
- -
- P/B
- 8.30x
- ROE
- -12.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4RY.F undervalued?
Graham numberThe Graham number of AKESO INC. O.N. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AKESO INC. O.N. fundamental analysis
No fundamental analysis for AKESO INC. O.N. yet.
AKESO INC. O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also deve…
Full company profileAKESO INC. O.N. financial statements
AKESO INC. O.N. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 226M | 838M | 4.53B | 2.12B | 3.06B |
| Gross Profit | 194M | 744M | 4.39B | 1.83B | 2.40B |
| Operating Income | -1.27B | -1.20B | 2.17B | -504M | -848M |
| EBITDA | - | -1.27B | 2.17B | -239M | -748M |
| Net Income | -1.07B | -1.17B | 2.03B | -515M | -1.11B |
| EPS | -1.32 | -1.39 | 2.41 | -0.57 | -1.21 |
| Balance Sheet | |||||
| Total Assets | 4.81B | 5.50B | 9.18B | 12.8B | 16.0B |
| Total Liabilities | 1.53B | 2.95B | 4.66B | 6.00B | 7.05B |
| Shareholders' Equity | 3.16B | 2.64B | 4.69B | 6.81B | 9.05B |
| Cash & Short-term Investments | 2.64B | 2.09B | 4.03B | 6.89B | 8.78B |
| Cash Flow | |||||
| Operating Cash Flow | -1.00B | -1.24B | 2.47B | -528M | -948M |
| Capital Expenditure | 716M | 802M | 879M | 594M | 787M |
| Free Cash Flow | -1.72B | -2.04B | 1.59B | -1.12B | -1.73B |
| Ratios | |||||
| ROE | -34.0% | -44.3% | 43.2% | -7.6% | -12.3% |
| ROA | -22.4% | -21.3% | 22.1% | -4.0% | -7.0% |
| Net Profit Margin | -476.4% | -139.5% | 44.8% | -24.2% | -36.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AKESO INC. O.N. dividends
AKESO INC. O.N. has not paid dividends in the last 5 fiscal years.
Who owns AKESO INC. O.N.
- Insiders 21.21%
- Institutions 32.28%
- Public & others 46.51%
- Shares outstanding 941M
- Free float 726M
AKESO INC. O.N. company profile
- Company name
- AKESO INC. O.N.
- Ticker
- 4RY.F
- ISIN
- KYG0146B1032
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,082
- Fiscal year end
- December
- Address
- No. 6, Shennong Road, Zhongshan, China, 528437
- Phone
- 86 760 8987 3998
- Website
- akesobio.com
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK120 to treat moderate-to-severe atopic dermatitis. The company was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.
AKESO INC. O.N. management
10- Dr. Baiyong Li Ph.D.Co-Founder, Executive VP, CSO & Executive Director · born 1969
- Dr. Zhongmin Wang Ph.D.Co-Founder, Senior VP & Executive Director · born 1969
- Dr. Peng Zhang Ph.D.Co-Founder, Senior VP & Executive Director · born 1976
- Mr. Yu Xia Ph.D.Senior Vice President · born 1971
- Dr. Yu Xia Ph.D.Founder, CEO, President & Chairwoman · born 1967
- Dr. Bing C. Wang M.B.A., Ph.D.Chief Financial Officer · born 1977
- Dr. Mingxiu Hu Ph.D.Senior Vice President
- Dr. Xinfeng Zhang Ph.D.Senior Vice President
- Dr. Jing Min Ph.D.Senior Vice President
- Mr. Yong GuoSenior VP & Chief Commercial Officer · born 1970